Hypertrichosis, Trichomegaly, and Androgenic Alopecia Related to Cetuximab Treatment

Cetuximab, an anti-EGFR monoclonal antibody used in treating metastatic colorectal carcinoma and head and neck cancers, was reported to cause dermatological toxicities including hypertrichosis, trichomegaly, and alopecia. A case study of a 39-year-old female with metastatic colon cancer treated with cetuximab and chemotherapy developed these conditions. Despite normal hormonal levels and adrenal imaging, the patient exhibited increased facial and body hair, androgenic alopecia, and trichomegaly. This combination of symptoms was attributed to cetuximab disrupting hair follicle differentiation and growth, a unique presentation not previously documented in the literature.